Specialized Cancer Center Support Grant

专门癌症中心支持补助金

• 批准号: 10230260
• 负责人: SCOTT M LIPPMAN
• 金额: $ 9.32万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10230260
• 关键词: Academia; Address; Applications Grants; Area; Basic Science; Bioinformatics; Biological; Biological Sciences; Biology; Biometry; Breast; California; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Control Research; Cancer Etiology; Cancer Patient; Caring; Catchment Area; Cause of Death; Cessation of life; Clinic; Clinical; Clinical Data; Clinical Protocols; Clinical Research; Clinical Trials; Collaborations; Colon Carcinoma; Colorectal; Colorectal Cancer; Communities; Community Outreach; Comprehensive Cancer Center; Computational Biology; County; Death Rate; Development; Diabetes Mellitus; Diagnostic; Education; Engineering; Environment; Flow Cytometry; Fostering; Funding; Genomics; Goals; Growth; Health Sciences; Health system; Hematologic Neoplasms; Hispanics; Hospitals; Image; Individual; Infrastructure; Institutes; Lateral; Leadership; Linguistics; Liver; Liver Cirrhosis; Lung; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Medical; Medically Underserved Area; Mexico; Microscopy; Mission; Monitor; Neoplasms; Obesity; Ovary; Pancreas; Peer Review; Peer Review Grants; Pharmacologic Substance; Pharmacy facility; Population; Population Density; Population Research; Preventive; Prostate; Protocols documentation; Research; Research Personnel; Research Support; Research Training; Resource Sharing; Risk Factors; Science; Signal Transduction; Solid Neoplasm; Systems Biology; Technology; Testing; Therapeutic; Tissues; Training; Training and Education; Transgenic Mice; Translating; Translational Research; Translations; Underinsured; Underrepresented Minority; Uninsured; United States; United States Health Resources and Services Administration; Universities; University resources; Vulnerable Populations; Woman; anticancer research; base; biobank; biobehavior; cancer care; cancer education; cancer health disparity; cancer prevention; clinical care; cost; data management; diagnostic biomarker; ethnic diversity; functional genomics; industry partner; innovation; investigator-initiated trial; male; medical schools; member; men; mortality; multidisciplinary; next generation; novel; outreach; outreach program; physical science; prevent; programs; racial and ethnic; screening; structural genomics; tumorigenesis

OVERALL ABSTRACT Founded in 1977 by John Mendelsohn, the Cancer Center at University of California San Diego (UCSD) has been continuously funded by the NCI Cancer Center Support Grant (CCSG) since 1978 and has held Comprehensive status since 2001. As the only NCI-designated Comprehensive Cancer Center in San Diego County, the mission of Moores Cancer Center (MCC) is to reduce the impact of cancer in the region and beyond by fostering scientific discovery, research training, and interdisciplinary care. Our goal is to create, translate, and deliver high-impact discoveries and innovations in cancer prevention and care through a deep understanding of the needs of the catchment area, and prepare the next generation of cancer researchers. Accordingly, MCC’s aims are to: 1) Elucidate the biology of cancer and catalyze trans-disciplinary team science across the science spectrum; 2) Develop and test innovative preventive, diagnostic, and therapeutic approaches; 3) Conduct cancer prevention and control research to reduce cancer disparities in vulnerable populations; 4) Provide underrepresented minorities with access to cutting edge multi-disciplinary care; 5) Provide training and education across the trainee continuum; and 6) Develop and implement community-based cancer education and outreach programs. To this end, MCC brings together 232 members from 5 UCSD Schools (Medicine, Engineering, Pharmacy and Pharmaceutical Sciences, Physical Sciences and Biological Sciences) and 2 consortium partners (one existing: San Diego State University, and one new: La Jolla Institute). Furthermore, MCC integrates the resources of UCSD Health Sciences and its affiliated hospitals in the UCSD Health System for a unified approach to cancer research and clinical care. MCC fulfills its mission through the activities of its 5 Research Programs (Cancer Biology and Signaling, Structural and Functional Genomics, Solid Tumor Therapeutics, Hematological Malignancies, and Cancer Control) that are supported by 7 Shared Resources (Flow Cytometry, Microscopy, Transgenic Mouse, Biostatistics, Genomics and Computational Biology, Biorepository and Tissue Technology, and Biobehavioral), and infrastructure provided by Community Outreach, Training and Education, Clinical Protocol and Data Management, and Protocol Review and Monitoring. Under the leadership of Dr. Scott Lippman, Center Director and Associate Vice- Chancellor for Cancer Research and Care, MCC has seen tremendous growth. During the project period, MCC members authored 3931 cancer-relevant research articles, and in 2017 were supported by $128.2 million (DC) in annual cancer-relevant peer-reviewed funding (8% increase); and the total annualized cancer-relevant research base was $148.5M, an increase of 11% from the previous project period by lateral comparison. Collaborative peer-reviewed grant funding also increased from annual total costs of $65.9M in 2013 to $69.9M in 2017 (6% increase). Importantly, 33 of MCC’s scientific discoveries were translated to the clinic through 41 investigator-initiated clinical trials, a 14-fold increase from the previous project period.

总体摘要 加州圣地亚哥大学（UCSD）癌症中心由约翰·门德尔松（John Mendelsohn）于1977年创立， 自1978年以来一直由NCI癌症中心支持补助金（CCSG）资助， 自2001年以来的全面状况。作为圣地亚哥唯一一家NCI指定的综合癌症中心， 县，摩尔癌症中心（MCC）的使命是减少癌症在该地区的影响， 通过促进科学发现，研究培训和跨学科护理。我们的目标是创造， 翻译，并提供高影响力的发现和创新，在癌症预防和护理，通过一个深刻的 了解集水区的需求，并为下一代癌症研究人员做好准备。 因此，MCC的目标是：1）阐明癌症的生物学，促进跨学科团队 跨科学范围的科学; 2）开发和测试创新的预防，诊断和治疗 3）开展癌症预防和控制研究，以减少弱势群体中的癌症差异 4）为代表性不足的少数民族提供最先进的多学科护理; 5） 为所有受训者提供培训和教育;以及6）制定和实施基于社区的 癌症教育和外展计划。为此，MCC汇集了来自5个UCSD的232名成员 学校（医学、工程、药学和制药科学、物理科学和生物科学） 科学）和2个联盟合作伙伴（一个现有的：圣地亚哥州立大学，一个新的：拉霍亚 研究所）。此外，MCC整合了UCSD健康科学及其附属医院的资源， UCSD卫生系统为癌症研究和临床护理提供统一的方法。MCC履行其使命 通过其5个研究项目（癌症生物学和信号传导，结构和功能）的活动， 基因组学、实体瘤治疗、血液肿瘤和癌症控制）， 7共享资源（流式细胞术，显微镜，转基因小鼠，生物统计学，基因组学和 计算生物学、生物储存和组织技术以及生物行为），并提供基础设施 按社区外展、培训和教育、临床方案和数据管理以及方案 审查和监测。在中心主任兼副主任Scott Lippman博士的领导下， MCC癌症研究和护理大臣见证了巨大的增长。在项目期间，MCC 成员撰写了3931篇与癌症相关的研究文章，2017年获得了1.282亿美元的支持（DC） 年度癌症相关同行评审资金（增加8%）;以及年度癌症相关资金总额 研究基础为1.485亿美元，横向比较比上一个项目期增加了11%。 合作同行评审赠款资金也从2013年的年度总成本6590万美元增加到6990万美元 2017年（增长6%）。重要的是，MCC的33项科学发现被转化为临床， 制药商发起的临床试验，比上一个项目期增加了14倍。